Abstract: A microfluidic device for measuring T cell deformability and/or capillary network occlusion includes at least one microchannel configured to receive a fluid sample containing T cells that flows along a length of the microchannel and includes a plurality of micropillar arrays provided along the length of the microchannel in a direction of fluid flow through the microchannel, wherein each micropillar array defines a plurality of microcapillaries each having a width and the widths of the microcapillaries defined by each micropillar array decreases in a direction of fluid flow through the microchannel.

Abstract: A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.

Abstract: A method of determining at least one of hemoglobin oxygen affinity, rate of hemoglobin deoxygenation, or the presence of hemoglobin variants in blood of a subject, the method includes determining differences of absorption spectra of oxygenated and deoxygenated hemoglobin, red blood, and/or blood obtained from the subject and comparing the determined absorption spectra differences to a control value, wherein the absorption spectra differences are indicative of hemoglobin oxygen affinity, rate of hemoglobin deoxygenation, or the presence of hemoglobin variants in the blood of the subject.

Abstract: This application describes a microfluidic system for measuring blood flow velocity using particle image velocimetry (PIV) and wavelet-based optical flow velocimetry (wOFV) processing to determine one or more hemodynamic parameters. The hemodynamic parameters can include whole blood rheology as well as spatiotemporal variations in blood velocity, respectively, during coagulation in flowing blood samples. The system can provide quantitative information on the formation and evolution of thrombi, identify subjects with clotting disorders associated with abnormal thrombus growth rate, and/or determine the effect of therapeutics and/or therapeutical approaches on clotting dynamics and thrombus formation.

Abstract: An example system includes one or more non-transitory machine-readable media and one or more processors. The non-transitory machine-readable media is configured to store data and instructions, in which the data includes image data having a plurality of image frames of an electrophoresis process performed on a sample over a time interval. The sample contains at least one analyte. The one or more processors are configured to access the data and execute the instructions, in which the instructions programmed to perform a method. The method can include determining values of pixels within a region of interest (ROI) of respective image frames in the time interval. The method can also include analyzing the determined pixel values for at least some of the respective image frames. The method can also include estimating a quantity of the at least one analyte in the sample based on the analysis of the pixel values.

Abstract: A point-of-care diagnostic system that includes a cartridge and a reader. The cartridge can contain a patient sample, such as a blood sample. The cartridge is inserted into the reader and the patient sample is analyzed. The reader contains various analysis systems, such as an electrophoresis detection system that uses electrophoresis testing to identify and quantify various components of the blood sample. The reader can process data from the various patient sample analysis to provide interpretative results indicative of a disorder, condition, disease and/or infection of the patient.

Abstract: In a disclosed example, a computer-implemented method includes storing image data that includes an input image of a blood sample within a blood monitoring device. The method also includes generating, by a machine learning model, a segmentation mask that assigns pixels in the input image to one of a plurality of classes, which correlate to respective known biophysical properties of blood cells. The method also includes extracting cell images from the input image based on the segmentation mask, in which each extracted cell image includes a respective cluster of the pixels assigned to a respective one of the plurality of classes.

Abstract: A diagnostic system detects and/or measures hemoglobin variants in blood of subject, such as HbA1c, to determine blood glucose concentration in the subject.

Abstract: A microfluidic system for measuring cell adhesion includes a gas impermeable housing including at least one microchannel defining at least one cell adhesion region, the at least one cell adhesion region being provided with at least one capturing agent that adheres a cell of interest to a surface of the at least one microchannel when a fluid sample containing cells is passed through the at least one microchannel, and an imaging system for measuring the adherence of cells of interest adhered by the at least one capturing agent to the surface of the at least one microchannel when the fluid sample is passed therethrough.

Abstract: A microfluidic device includes at least one microchannel with a plurality of micropillar arrays provided along a length of the microchannel. Each micropillar array defines a plurality microcapillaries having cross sectional area, and the cross sectional area of the microcapillaries defined by each micropillar array decreases in a direction of fluid flow through the microchannel.

Abstract: A diagnostic system detects and/or measures hemoglobin and/or hemoglobin variants in blood of subject to determine hemoglobin levels, hemoglobin variants, and/or anemia in the subject.

Abstract: A diagnostic system detects and/or measures hemoglobin variants in blood of subject, such as HbA1c, to determine blood glucose concentration in the subject.

Abstract: As one example, a fluid monitoring apparatus includes a dielectric microsensor that includes a capacitive sensing structure integrated into a microfluidic channel. The microfluidic channel includes a fluid input to receive a sample volume of a sample under test (SUT). A transmitter provides an input radio frequency (RF) signal to an RF input of the microsensor. A receiver receives an output RF signal from the microsensor. A computing device computes dielectric permittivity values of the SUT that vary over a time interval based on the output RF signal. The computing device may determine an indication of platelet count based on the computed dielectric permittivity values over at least a portion of the time interval.

Abstract: As one example, a fluid monitoring apparatus includes a dielectric microsensor that includes a capacitive sensing structure integrated into a microfluidic channel. The microfluidic channel includes a fluid input to receive a sample volume of a sample under test (SUT). A transmitter provides an input radio frequency (RF) signal to an RF input of the microsensor. A receiver receives an output RF signal from the microsensor. A computing device computes dielectric permittivity values of the SUT that vary over a time interval based on the output RF signal. The computing device may determine at least one permittivity parameter based on the computed dielectric permittivity values over at least a portion of the time interval.

Abstract: A microfluidic biochip device includes a housing including at least one microchannel defining at least one cell adhesion region. The at least one cell adhesion region is provided with at least one capturing agent that adheres a cell of interest to a surface of the at least one microchannel when a fluid sample containing cells is passed through the at least one microchannel. An imaging system measures the morphology and/or quantity of cells of interest adhered by the at least one capturing agent to the surface of the at least one microchannel when the fluid sample is passed therethrough.

Abstract: Disease components can be detected in a fluid using magnetic particles and microfluidics. Magnetic particles are combined with a sample in a fluid. The sample may include disease components. The magnetic particles can be configured to tag any disease components within the sample. The fluid can be forced into a microchamber with two microcompartments. In the first microcompartment, the fluid can be exposed to a magnetic field and/or magnetic field gradient. The tagged disease component can be trapped by the magnetic field and/or magnetic field gradient due to the magnetic particles, allowing nonmagnetic components of the fluid to be washed away while the tagged disease components remain trapped by the magnetic field and/or magnetic field gradient. Then, the disease components can be forced into a more narrow second microcompartment and detected using optical instruments.

Abstract: A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.

Abstract: As one example, a fluid monitoring apparatus includes a dielectric microsensor that includes a capacitive sensing structure integrated into a microfluidic channel. The microfluidic channel includes a fluid input to receive a sample volume of a sample under test (SUT). A transmitter provides an input radio frequency (RF) signal to an RF input of the microsensor. A receiver receives an output RF signal from the microsensor. A computing device computes dielectric permittivity values of the SUT that vary over a time interval based on the output RF signal. The computing device may determine at least one permittivity parameter based on the computed dielectric permittivity values over at least a portion of the time interval.

Abstract: A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.

Abstract: A sensor system can be configured to perform dielectric spectroscopy (DS). For example, the system can include a sensor configured to measure dielectric permittivity of a fluid in response to an RF input signal. Associated interface electronics can include a transmitter to drive the sensor with the RF input signal and a receiver to receive and process an RF output signal from the sensor in response to the RF input signal.